Login / Signup

Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study.

Naoki IwamotoShuntaro SatoKaori FurukawaToru MichitsujiKazuteru ShiraishiKounosuke WatanabeKo ChibaMakoto OsakiAtsushi Kawakami
Published in: Modern rheumatology (2024)
Denosumab may inhibit bone destruction by suppressing bone-related factors/chemokines.
Keyphrases
  • bone mineral density
  • open label
  • postmenopausal women
  • clinical trial
  • body composition
  • study protocol
  • soft tissue
  • bone loss
  • bone regeneration
  • squamous cell carcinoma
  • radiation therapy
  • cross sectional
  • phase iii